Lasgrain Tablet 50 mg contains Lasmiditan Hemisuccinate, a novel and selective serotonin (5-HT1F) receptor agonist developed specifically for the acute treatment of migraine attacks with or without aura in adults. Unlike traditional migraine therapies such as triptans, Lasgrain does not cause vasoconstriction, making it a suitable option for patients who have cardiovascular risk factors or contraindications to vasoconstrictive agents.

Lasgrain is intended for acute migraine relief and is not indicated for migraine prevention.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Anti-migraine agents
Selective serotonin 5-HT1F receptor agonist (Ditans)

Indications

Lasgrain Tablet 50 mg is indicated for:

• Acute treatment of migraine with or without aura in adult patients

• Patients who are unable to tolerate or are contraindicated for triptans due to cardiovascular conditions

Lasgrain is not indicated for the prevention of migraine or for the treatment of cluster headaches.

Pharmacology

Lasmiditan is a highly selective 5-HT1F receptor agonist that exerts its therapeutic effect by inhibiting trigeminal nerve pathways involved in migraine pathophysiology. Activation of 5-HT1F receptors reduces the release of pro-inflammatory neuropeptides and decreases pain signal transmission within the central nervous system.

Unlike triptans, Lasmiditan has no significant activity at 5-HT1B or 5-HT1D receptors, which are responsible for vasoconstriction. As a result, Lasgrain provides effective migraine relief without causing constriction of cranial or coronary blood vessels.

Lasmiditan is rapidly absorbed following oral administration, with peak plasma concentrations typically achieved within 1.5 to 2 hours.

Dosage & Administration

• Recommended dose: 50 mg taken orally as a single dose at the onset of a migraine attack

• Tablets should be swallowed whole with water and may be taken with or without food

If the migraine persists, no more than one dose should be taken within 24 hours. The maximum recommended dosage is one tablet per day.

Patients should be advised that Lasgrain may cause central nervous system effects, and activities requiring mental alertness should be avoided after dosing.

Drug Interactions

• Central nervous system depressants: Concomitant use may increase sedation or dizziness

• Serotonergic drugs: Use with caution due to the potential risk of serotonin syndrome

• Alcohol: May enhance CNS depressant effects and should be avoided

Dose adjustments may be required when used with strong inhibitors or inducers of drug-metabolizing enzymes.

Contraindications

• Known hypersensitivity to Lasmiditan or any excipients of the formulation

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

The most commonly reported adverse reactions include:

• Dizziness

• Fatigue

• Somnolence

• Paresthesia

• Nausea

Most side effects are mild to moderate in severity and typically resolve without intervention.

Precautions & Warnings

• Driving impairment: Patients should not drive or operate machinery for at least 8 hours after taking Lasgrain

• Central nervous system depression: Caution is advised, especially when combined with alcohol or sedatives

• Serotonin syndrome: Monitor patients receiving concomitant serotonergic medications

Pregnancy & Lactation

• Pregnancy: Limited data are available. Lasgrain should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

• Lactation: It is unknown whether Lasmiditan is excreted in human milk. Caution is advised when administered to breastfeeding women

Storage Conditions

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Mode of Action

Lasgrain works by selectively activating 5-HT1F receptors in the trigeminal system, leading to inhibition of pain pathways associated with migraine attacks. This targeted mechanism provides effective migraine relief without causing vasoconstriction, distinguishing Lasgrain from conventional migraine therapies.